Open Orphan #ORPH Announces New £2.5m Influenza Challenge Study Contract Win
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce the signing of a £2.5 million contract by hVIVO, a subsidiary of Open Orphan, to conduct an Influenza human challenge study with […]
Open Orphan #ORPH – Interim Results for 6 months ended 30 June, will be operationally profitable in Q4
Open Orphan Plc, a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical studies is pleased to announce its interim results for the six months ended 30 June 2020. The interim results include the first six months of hVIVO group (“hVIVO”) following its […]
The Times – Trial to infect British volunteers with modified coronavirus at hVIVO Quarantine Centre
Scientists are planning to infect British volunteers with a weakened, computer-designed form of the coronavirus, which researchers believe could work as a vaccine. The early-stage trial will take place in a special 24-bed quarantine clinic in Whitechapel, east London. The US biotech company behind it, Codagenix, is in talks with UK regulators and expects to […]
Open Orphan #ORPH – New £4.3m Challenge Study Contract Win with Global Top 10 Vaccine Company
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new £4.3 million contract to conduct a human viral challenge study utilising one of our 8 traditional challenge study models for another […]
Open Orphan #ORPH Awarded Contract From Codagenix Inc For COVID-19 Vaccine Trial
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new contract with Codagenix Inc. (“Codagenix”) to conduct a first in human (Phase I) trial evaluating safety and immunogenicity of a single-dose, […]
Open Orphan plc #ORPH – Launch of Covid-19 Antibody Testing
Open Orphan plc (“Open Orphan” or the “Company”) Launch of Covid-19 Antibody Testing Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models, announces the launch of hVIVO COVID Clear Test, the Company’s antibody testing […]
Open Orphan #ORPH – Results of Fundraising
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is the world leader in the testing of vaccines and antivirals using human challenge study models, announces that, further to its announcement at 7.00 a.m. today (the “Fundraising Announcement”), it has successfully completed the oversubscribed […]
Open Orphan #ORPH – Proposed Fundraising to raise up to £12 million and PrimaryBid.com Offer
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is the world leader in the testing of vaccines and antivirals using human challenge study models, today announces its intention to raise up to £12 million (net of expenses) (the “Fundraising”) via a placing of […]
Open Orphan #ORPH – Update on antibody test agreement and recent share price movement
Open Orphan plc (ORPH) the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is the world leader in the testing of vaccines and antivirals using human challenge study models, notes the increase in the Company’s share price and media comment regarding its collaboration with Quotient Limited. Furthermore, it […]
Open Orphan Chairman Cathal Friel speaks to BRR Media re the new contract, other developments and the CEO’s departure
Open Orphan PLC’s (LON:ORPH) Cathal Friel speaks to Rosie Riall at BRR Media after signing a new deal with a US biotech for the provision of a respiratory syncytial virus human challenge study. Cathal also covers the channel pipeline, the hVIVO quarantine centre, flu and malaria vaccines and the planned departure of CEO Trevor Phillips.